Everolimus, a mammalian target of rapamycin inhibitor, ameliorated streptozotocin-induced learning and memory deficits via neurochemical alterations in male rats

Simple item page
dc.contributor.authorFanoudi, Sahar
dc.contributor.authorHosseini, Mahmoud
dc.contributor.authorAlavi, Mohaddeseh Sadat
dc.contributor.authorBoroushaki, Mohammad Taher
dc.contributor.authorHosseini, Azar
dc.contributor.authorSadeghnia, Hamid R.
dc.date.accessioned2019-03-25T07:59:39Z
dc.date.available2019-03-25T07:59:39Z
dc.date.issued2018-10-29
dc.description.abstractEverolimus (EVR), as a rapamycin analog, is a selective inhibitor of the mammalian target of rapamycin (mTOR) kinase and its associated signaling pathway. mTOR is a serine/threonine protein kinase and its hyperactivity is involved in the pathophysiology of Alzheimer’s disease (AD) and associated cognitive deficits. The present study evaluated the impact of EVR, on cognitive functions, hippocampal cell loss, and neurochemical parameters in the intracerebroventricular streptozotocin (icv-STZ) model of AD rats. EVR (1 and 5 mg/kg) was administered for 21 days following the single administration of STZ (3 mg/kg, icv) or for 7 days on days 21-28 post-STZ injection after establishment of cognitive dysfunction. Cognitive deficits (passive avoidance and spatial memory), oxidative stress parameters, acetylcholinesterase (AChE) activity, and percentage of cell loss were evaluated in the hippocampus. Chronic administration (1 and 5 mg/kg for 21 days from the day of surgery and icv-STZ infusion) or acute injection (5 mg/kg for 7 days after establishment of cognitive impairment) of EVR significantly attenuated cognitive dysfunction, neuronal loss, oxidative stress and AChE activity in the hippocampus of STZ-AD rats. In conclusion, our study showed that EVR could prevent or improve deteriorations in behavioral, biochemical and histopathological features of the icv-STZ rat model of AD. Therefore, inhibition of the hyperactivated mTOR may be an important therapeutic target for AD.en
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/37957
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-19942
dc.language.isoen
dc.relation.ispartofseriesEXCLI Journal;Vol. 17 2018
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectEverolimusen
dc.subjectmTORen
dc.subjectAlzheimer’s disease (AD)en
dc.subjectOxidative stressen
dc.subjectAcetylcholinesteraseen
dc.subjectStreptozotocinen
dc.subject.ddc610
dc.titleEverolimus, a mammalian target of rapamycin inhibitor, ameliorated streptozotocin-induced learning and memory deficits via neurochemical alterations in male ratsen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.zdberstkatid2132560-1
eldorado.secondarypublicationtrue

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Sadeghnia_29102018_proof.pdf
Size:
785.11 KB
Format:
Adobe Portable Document Format
Description:
DNB
Download
Thumbnail Image
Name:
Sadeghnia_29102018_supplementary_data.pdf
Size:
97.36 KB
Format:
Adobe Portable Document Format
Description:
DNB
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Original Articles